by NDASA | Jan 23, 2024 | Marijuana & CBD, Substance Use
By Buzzkill Labs Although state lawmakers approved Assembly Bill 2188 more than a year ago, there is still a lack of clarity about what it means for employers in California. Even some drug testing service providers are under the impression that AB 2188 spells the end...
by Guest Contributer | Sep 11, 2023 | Drug & Alcohol Testing, Feature, Marijuana & CBD, Newsletter Only, Workplace Safety
|by Bill Current This article was written by Bill Current of the Current Consulting Group (CCG) on behalf of Premier Biotech for publication by NDASA. For further information about the subjects covered in this article, please email Bill...
by Guest Contributer | Mar 1, 2022 | Drug Legislation, Feature
By Bill Current, president and founder of the Current Consulting Group and publisher of Current Compliance* State drug testing laws can be complicated. Why? First, because there are so many of them. Second, because there are various kinds. For instance, there are:...
by NDASA | Feb 24, 2022 | Advocacy, Drug & Alcohol Testing, Drug Legislation, Feature
From a Member’s Memo podcast with NDASA Executive Director Jo McGuire.* From time to time, we receive calls from members questioning the National Drug and Alcohol Screening Association’s work in our nation’s capital and why our organization would need a...
by Guest Contributer | May 21, 2021 | Drug Legislation, Feature, Marijuana & CBD
By guest contributors Bill Judge, JD, LL.M., and Nick Hartman of the Drug Screening Compliance Institute State and local marijuana laws around the country are fast-changing and often confusing. In this article NDASA members Bill Judge and Nick Hartman take on recent...
by NDASA | Apr 23, 2021 | For Drug Testing Industry Professionals, For Employers and Workplace Safety & Wellness Professionals, Marijuana & CBD, Resources
The Institute for Behavior and Health, Inc., is a nonprofit organization based in Rockville, Md., that develops strategies to reduce drug use. President Robert L. DuPont, M.D., was the lead author on an extensive 2015 report titled, “Workplace Drug Testing in the Era...
by NDASA | Apr 23, 2021 | For Drug Testing Industry Professionals, Marijuana & CBD, Resources
“Medical Review Officers will not verify a drug test as negative based upon information that a physician recommended that the employee use “medical marijuana.” Please note that marijuana remains a drug listed in Schedule I of the Controlled Substances Act. It remains...
by NDASA | Apr 23, 2021 | For Employers and Workplace Safety & Wellness Professionals, Marijuana & CBD, Resources
Marijuana is an impairing substance. The user experiences reduced motor coordination, short-term memory loss and altered reaction time, all of which has destructive effects in the workplace. High doses of THC, the active ingredient in the cannabis plant, can cause...
by NDASA | Oct 23, 2020 | Drug Legislation, Feature, NDASA Guidance
The Procedures for Transportation Workplace Drug and Alcohol Testing Program outlined in 49 CFR Part 40 applies to transportation safety-sensitive employees who have a direct impact on the safety of commercial transportation for both the traveling...
